Skip to main content

Advertisement

SpringerLink
Log in

Temozolomide single-agent chemotherapy for newly diagnosed anaplastic oligodendroglioma

  • Clinical study - patients study
  • Published:
Journal of Neuro-Oncology Aims and scope Submit manuscript

Abstract

The treatment of patients with anaplastic oligodendroglioma (AO) has been significantly impacted by the molecular detection of loss of sequences on chromosomes 1p and 19q. We performed a clinical trial to prospectively evaluate the safety of treating patients with AO with temozolomide (TMZ) alone in patients with chromosome 1p/19q loss and with chemo-radiation in patients not harboring this loss. Forty-eight patients were enrolled, 36/48 (75%) with evidence of chromosome 1p/19q loss treated with TMZ alone and 12/18 (25%) without such losses, treated with pre-radiation TMZ followed by chemo-radiation. Despite more aggressive treatment, patients without 1p/19q loss had a shorter progression-free survival (PFS) of 13.5 months. With a median follow-up time of 32 months, patients with 1p/19q LOH had a median TTP of 28.7 months. Patients with AO with 1p/19q LOH can be safely treated with single-agent TMZ and do not appear to experience earlier or more frequent tumor progression. This treatment regimen should be studied as part of a formal randomized clinical trial.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Cairncross JG, Ueki K, Zlatescu MC et al (1998) Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 90:1473–1479. doi:10.1093/jnci/90.19.1473

    Article  PubMed  CAS  Google Scholar 

  2. Ino Y, Betensky RA, Zlatescu MC et al (2001) Molecular subtypes of anaplastic oligodendroglioma: implications for patient management at diagnosis. Clin Cancer Res 7:839–845

    PubMed  CAS  Google Scholar 

  3. Jenkins RB, Blair H, Ballman KV et al (2006) A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma. Cancer Res 66:9852–9861. doi:10.1158/0008-5472.CAN-06-1796

    Article  PubMed  CAS  Google Scholar 

  4. Cairncross G, Berkey B, Shaw E et al (2006) Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402. J Clin Oncol 24:2707–2714. doi:10.1200/JCO.2005.04.3414

    Article  PubMed  CAS  Google Scholar 

  5. van den Bent MJ, Carpentier AF, Brandes AA et al (2006) Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European organisation for research and treatment of cancer phase III trial. J Clin Oncol 24:2715–2722. doi:10.1200/JCO.2005.04.6078

    Article  PubMed  CAS  Google Scholar 

  6. Mohile N, Forsyth P, Stewart D et al (2008) A phase II study of intensified chemotherapy alone as initial treatment for newly diagnosed anaplastic oligodendroglioma: an interim analysis. J Neurooncol 89:187–193. doi:10.1007/s11060-008-9603-8

    Article  PubMed  CAS  Google Scholar 

  7. Kouwenhoven MC, Kros JM, French PJ et al (2006) 1p/19q loss within oligodendroglioma is predictive for response to first line temozolomide but not to salvage treatment. Eur J Cancer 42:2499–2503. doi:10.1016/j.ejca.2006.05.021

    Article  PubMed  CAS  Google Scholar 

  8. Taliansky-Aronov A, Bokstein F, Lavon I, Siegal T (2006) Temozolomide treatment for newly diagnosed anaplastic oligodendrogliomas: a clinical efficacy trial. J Neurooncol 79:153–157. doi:10.1007/s11060-005-9020-1

    Article  PubMed  CAS  Google Scholar 

  9. Abrey LE, Louis DN, Paleologos N et al (2007) Oligodendroglioma study G: survey of treatment recommendations for anaplastic oligodendroglioma. Neuro Oncol 9:314–318. doi:10.1215/15228517-2007-002

    Article  PubMed  CAS  Google Scholar 

  10. Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG (1990) Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8:1277–1280

    PubMed  CAS  Google Scholar 

  11. Bogler O, Newsham I (2002) Studying the heterogeneity of brain tumors using medium throughput LOH analysis. Cytometry 47:52–55. doi:10.1002/cyto.10035

    Article  PubMed  Google Scholar 

  12. Cairncross J, Macdonald D, Ramsay D (1992) Aggressive oligodendroglioma: A chemosensitive tumor. Neurosurgery 3:78–82

    Article  Google Scholar 

  13. Bryant J, Day R (1995) Incorporating toxicity considerations into the design of two-stage phase II clinical trials. Biometrics 51:1372–1383. doi:10.2307/2533268

    Article  PubMed  CAS  Google Scholar 

  14. Cankovic M, Mikkelsen T, Rosenblum ML, Zarbo RJ (2007) A simplified laboratory validated assay for MGMT promoter hypermethylation analysis of glioma specimens from formalin-fixed paraffin-embedded tissue. Lab Invest 87:392–397

    PubMed  CAS  Google Scholar 

  15. Esteller M, Garcia-Foncillas J, Andion E et al (2000) Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 343:1350–1354. doi:10.1056/NEJM200011093431901

    Article  PubMed  CAS  Google Scholar 

Download references

Disclosure

Conflicts of interest – research support was provided by Schering.

Author information

Authors and Affiliations

  1. Hermelin Brain Tumor Center, Henry Ford Health System, 2799 W Grand Blvd, Detroit, MI, 48202, USA

    T. Mikkelsen, T. Doyle, J. Anderson, J. Gutierrez, D. Croteau, L. Hasselbach & R. Avedissian

  2. Department of Neurology, Ford Hospital, Detroit, MI, USA

    T. Mikkelsen & L. Schultz

  3. Department of Neurosurgery, Ford Hospital, Detroit, MI, USA

    T. Mikkelsen, L. Hasselbach & L. Schultz

  4. Department of Biostatistics and Research Epidemiology, Ford Hospital, Detroit, MI, USA

    L. Schultz

  5. Department of Pathology, Ford Hospital, Detroit, MI, USA

    J. Gutierrez

  6. Department of Medical Oncology, Henry Ford Hospital, Detroit, MI, USA

    T. Doyle & J. Anderson

  7. Department of Medical Oncology, William Beaumont Hospital, Royal Oak, MI, USA

    J. Margolis

  8. Department of Neurology, Evanston Hospital, Evanston, IL, USA

    N. Paleologos

Authors
  1. T. Mikkelsen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. T. Doyle
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. J. Anderson
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. J. Margolis
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. N. Paleologos
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. J. Gutierrez
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. D. Croteau
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. L. Hasselbach
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. R. Avedissian
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. L. Schultz
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to T. Mikkelsen.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Mikkelsen, T., Doyle, T., Anderson, J. et al. Temozolomide single-agent chemotherapy for newly diagnosed anaplastic oligodendroglioma. J Neurooncol 92, 57–63 (2009). https://doi.org/10.1007/s11060-008-9735-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11060-008-9735-x

Keywords

Search

Navigation